A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64% in the DE111 group, while the proportion of normal stools decreased from 56% to 48% in the placebo group. In male participants specifically, the proportion of normal stools increased from 56% to 80%. In addition, a significant difference between the DE111 and placebo groups was observed in regards to normal and non-normal stool proportions in the 30+ age group.
Deerland Probiotics & Enzymes’ Probiotic DE111 First Bacillus subtilis to Attain Notified Food-Health Relationship Claims in Australia and New Zealand
Deerland Probiotics & Enzymes, a global supplier of science-backed solutions for microbiome health, is pleased to announce that its probiotic Bacillus…More
Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus…More